FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.

Ralf-Dieter HofheinzKirsten MerxGeorg M HaagChristoph SpringfeldThomas Jens Ettrich Kersten BorchertAlbrecht KretzschmarChristian TeschendorfGabriele SieglerMatthias P A EbertEray GoekkurtRolf MahlbergNils HomannDaniel PinkWolf BechsteinPeter ReichardtHagen FlachTimo GaiserAchim BattmannFuat S OduncuMaria LooseDisorn SookthaiClaudia PauligkThorsten O GöetzeSalah-Eddin Al-Batran

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

The addition of trastuzumab/pertuzumab to perioperative FLOT significantly improved pCR and nodal negativity rates at the price of higher rates of diarrhea and leukopenia.

Keyphrases

epidermal growth factor receptor
tyrosine kinase
advanced non small cell lung cancer
cardiac surgery
patients undergoing
endothelial cells
locally advanced
squamous cell carcinoma
neoadjuvant chemotherapy
lymph node
acute kidney injury
randomized controlled trial
pluripotent stem cells
rectal cancer
cell therapy